Dr. McDermott on Nivolumab Plus Ipilimumab in RCC
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).
The CheckMate-214 study evaluated the combination of PD-1 blockade with nivolumab and CTLA4 blockade with ipilimumab.
This combination was particularly impactful in patients who were intermediate- and poor-risk, as they demonstrated a longer progression-free survival, a significantly longer overall survival (OS), and a higher complete response rate, McDermott explains.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
